Benralizumab
Benralizumab is a monoclonal antibody therapy used as add-on maintenance treatment for severe eosinophilic asthma in patients aged 6 years and older. It works by binding to the interleukin-5 receptor on eosinophils, leading to their depletion and reducing airway inflammation.
A biologic agent for severe eosinophilic asthma that depletes eosinophils by targeting the IL-5 receptor.
Key facts at a glance
- ATC
- R03DX10
- RxNorm
- 1989100
- Generic
- Benralizumab
- Class
- atc-r03
- Brands
- Fasenra
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 30mg
- Maximum
- consult physician
- Frequency
- every 4 weeks for first 3 doses, then every 8 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 30mg
- Maximum
- consult physician
- Frequency
- every 4 weeks for first 3 doses, then every 8 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 30mg
- Maximum
- consult physician
- Frequency
- every 4 weeks for first 3 doses, then every 8 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second third trimesterdiscontinue if possible
consider discontinuation if pregnancy occurs; do not initiate during pregnancy
fetal growth monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedinguse with caution
decision to breastfeed should consider risk to infant and benefit of treatment
monitor infant for infections
geriatric
elderly 65no adjustment needed
no dose adjustment required for patients 65 years and older
standard monitoring
pediatric_age
adolescents 12 17no adjustment needed
approved for use in patients 12 years and older with severe eosinophilic asthma
standard monitoring
pediatric_age
children under 12not recommended
not approved for children under 12 years; limited safety and efficacy data
close monitoring if used off-label
Use with caution and monitor for adverse effects.
renal_impairment
mild moderateno adjustment needed
no dose adjustment required for mild to moderate renal impairment
standard monitoring
hepatic_impairment
mild moderateno adjustment needed
no dose adjustment required for mild to moderate hepatic impairment
standard monitoring
Statistics and clinical data
Drug class
Biologic medication classification
Common uses
Primary therapeutic indication
Mechanism of action
Pharmacological mechanism
Administration route
Method of delivery
Severe eosinophilic asthma as add-on maintenance therapy for patients 6 years and older who are inadequately controlled on high-dose inhaled corticosteroids plus long-acting beta-agonists
Binds with high affinity to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils, triggering antibody-dependent cell-mediated cytotoxicity that rapidly depletes circulating eosinophils, reducing airway inflammation
Administered subcutaneously every 4 weeks for first 3 doses, then every 8 weeks. Not for acute exacerbations. Monitor for hypersensitivity reactions and parasitic infections. Eosinophil depletion may affect response to certain infections.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy